6533b7dafe1ef96bd126f6b6

RESEARCH PRODUCT

The carriers of the A/G-G/G allelic combination of the c.2039 A>G and c.-29 G>A FSH receptor polymorphisms retrieve the highest number of oocytes in IVF/ICSI cycles

Riccardo AlessandroAntonio MaioranaAdolfo AllegraAngelo MarinoSalvatore GulloStefania RaimondoP. ScaglioneA Volpes

subject

0301 basic medicineAdultmedicine.medical_specialtyClinical variablesAdolescentGenotypePregnancy RateOocyte RetrievalFertilization in VitroBiology03 medical and health sciences0302 clinical medicineOvulation InductionPregnancyInternal medicineCOHmedicineGeneticsSNPHumansSperm Injections IntracytoplasmicAlleleGenetics (clinical)AllelesTreatment personalization030219 obstetrics & reproductive medicineIVF/ICSISurgery clinicObstetrics and GynecologyGeneral MedicineIvf icsiHuman genetics030104 developmental biologyEndocrinologyReproductive MedicineFSH receptor polymorphismOocytesReceptors FSHFemaleFsh receptor geneFollicle-stimulating hormone receptorDevelopmental Biology

description

The objective of this study was the elucidation of the possible role of the single-nucleotide polymorphisms (SNP) at position -29 and 2039 of the FSH receptor gene (FSHR) as independent predictive markers of ovarian response. Indeed, the tailoring of reproductive treatments is crucial for both maximizing the success of IVF patients and obtaining a reduction in hypo- or hyper-response rates. This prospective, observational study analyzed the association of -29 and 2039 FSHR polymorphisms with the number of retrieved oocytes in 140 patients attending an IVF/ICSI cycle for severe male factors (≤5,000,000 spermatozoa/mL) or tubal factors at the ANDROS Day Surgery Clinic, Palermo, Italy. The results of this study demonstrate that the genetic combination of A/G for polymorphism c.2039 A>G with G/G for polymorphism c.-29 G>A is significantly associated with the highest number of collected oocytes (p = 0.03). This association was significant even after controlling for the effect of other clinical variables. The A/G-G/G allelic variant, identified as an independent variable, if confirmed in a larger number of patients, could be considered as a new genetic biomarker, which could increase the efficacy of prediction models for ovarian stimulation.

10.1007/s10815-016-0835-9https://europepmc.org/articles/PMC5306403/